IIM
SAGE

INTECH Investment Management’s Sage Therapeutics SAGE Stock Holding History

INTECH Investment Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,541
Closed -$251K – 2506
2025
Q2 		$251K Sell
27,541
-1,581
-5% -$11.6K ﹤0.01% 1975
2025
Q1 		$232K Buy
29,122
+4,898
+20% +$35.9K ﹤0.01% 2016
2024
Q4 		$132K Buy
24,224
+3,950
+19% +$24.1K ﹤0.01% 2148
2024
Q3 		$146K Buy
+20,274
New +$186K ﹤0.01% 1811

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

INTECH Investment Management's SAGE Position: Q3 2025 in Review

INTECH Investment Management sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 27,541 shares — an estimated $251K sold.

INTECH Investment Management first reported a position in SAGE in Q3 2024 and held it in 4 quarters. The position peaked at $251K in Q2 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • INTECH Investment Management reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • INTECH Investment Management sold 27,541 Sage Therapeutics shares in Q3 2025, an estimated $251K.
  • INTECH Investment Management first reported a position in Sage Therapeutics in Q3 2024 and held it in 4 quarters.
  • INTECH Investment Management's Sage Therapeutics position peaked at $251K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on INTECH Investment Management's 13F filing for Q3 2025, filed 12 Nov 2025.